Drugs / PanBlok
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02464163 | Jul 2015 → Aug 2016 | influenza | Protein Sciences Corporation | Completed | No outcome recorded |
| Phase 1/2 | NCT01612000 | May 2012 → Aug 2013 | influenza | Protein Sciences Corporation | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Panblok | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02464163 ↗ |
| Modality | Vaccine | “recombinant hemagglutinin (rHA) influenza vaccine” NCT01612000 ↗ |
| Route | Intramuscular | “0.5mL intramuscular injection on Day 0 and Day 21 in the deltoid muscle” NCT01612000 ↗ |